Hillsdale Investment Management Inc. Makes New $1.08 Million Investment in Henry Schein, Inc. $HSIC

Hillsdale Investment Management Inc. bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,630 shares of the company’s stock, valued at approximately $1,078,000.

Several other large investors also recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in shares of Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after purchasing an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Henry Schein during the 1st quarter worth approximately $676,000. Cetera Investment Advisers raised its holdings in Henry Schein by 12.9% during the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after buying an additional 637 shares during the period. Finally, First Trust Advisors LP lifted its stake in Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after buying an additional 1,669 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Henry Schein news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.89% of the company’s stock.

Henry Schein Trading Up 1.3%

NASDAQ:HSIC opened at $88.26 on Friday. The company has a market cap of $10.05 billion, a P/E ratio of 26.66, a price-to-earnings-growth ratio of 1.68 and a beta of 0.81. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.34. The business has a 50 day moving average price of $79.16 and a two-hundred day moving average price of $77.64. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Analysts Set New Price Targets

HSIC has been the subject of several research analyst reports. Morgan Stanley reiterated an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Thursday, June 11th. BMO Capital Markets initiated coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price objective on the stock. UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $97.00 target price on Henry Schein in a report on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $87.64.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.